S
Seawolf Therapeutics
Redosable, non-viral DNA medicines for chronic diseases.
About Seawolf Therapeutics
Seawolf Therapeutics is a San Diego-based biotechnology company that launched in November 2026 after operating in stealth since 2021. The company was founded by CEO Elizabeth Alcamo, Ph.D., a former entrepreneur in residence for Versant Ventures with previous senior roles at CODA Biotherapeutics and 4D Molecular Therapeutics. Seawolf emerged with $100 million in financing from a seed round led by founding investor Versant Ventures, and a Series A round with backing from major players including MPM BioImpact, Novartis Venture Fund, Eli Lilly and Company, and CRISPR Therapeutics AG.
The company focuses on developing next-generation, non-viral DNA medicines. Its core technology is the TRIDENT™ platform, a redosable lipid nanoparticle (LNP)-based system designed to deliver DNA payloads into the cell's nucleus. This proprietary system aims to provide the long-term, stable expression of therapeutic proteins, overcoming the short-lived effects of RNA-based therapies while avoiding the immunogenicity and one-time-dosing limitations of viral-based gene therapies. The TRIDENT platform consists of a specialized LNP carrying an immune-quiet DNA and an auxiliary factor that helps it enter the nucleus, enabling durable and potent therapeutic effects that have been demonstrated in primate models.
Seawolf's business model combines in-house drug development with strategic partnerships. The company's lead proprietary program is advancing a candidate to address metabolic diseases, with preclinical models showing potential for treating obesity, muscle loss (sarcopenia), and osteoporosis. Concurrently with its public launch, Seawolf announced a multi-target research collaboration and exclusive license agreement with Sanofi. This partnership, valued at up to $1.2 billion in potential milestones plus royalties, is focused on developing therapies for bleeding disorders and other undisclosed indications.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Nov 2026 | $100M | $600M | Versant Ventures · Alexandria Venture Investments · CRISPR Therapeutics · Eli Lilly | ↗ |
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
PerturbMind AIAI-powered world model ecosystem for drug discovery. |
Jing'an District, China | Operational | — | — | — |
Lanexa BiologicsCommercial platform for biosimilar insulin therapies. |
— | Operational | |||
Claveritas PharmaBiotech & Life Sciences |
— | Operational | |||
XProteomeBiotech & Life Sciences |
East Lansing, United States | Operational | |||
Tamino BioProtein modulation platform for therapeutic target discovery. |
— | Operational | |||
Dimicare BiotechPrecision antibiotics for multidrug-resistant pathogens. |
Nice, France | Operational | |||
Lorikeet TherapeuticsInsulin-independent glucose uptake therapies for Type 1 Diabetes. |
Melbourne, Australia | Operational | |||
Celea TherapeuticsTherapeutics for serious and progressive respiratory diseases. |
Boston, United States | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Seawolf Therapeutics in the San Diego ecosystem
The Seawolf Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Versant Ventures
Alexandria Venture Investments
CRISPR Therapeutics
Eli Lilly
MPM BioImpact
Novartis Venture Fund
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Seawolf Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Seawolf Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









